Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211932 | 0.87 | MTNR1A (0.60) | ELANECTSGMTNR1AMTNR1BF2 | |
| SCHEMBL25591930 | 0.87 | MTNR1A (0.60) | ELANECTSGMTNR1AMTNR1BF2 | |
| SCHEMBL4028358 | 0.86 | ABCB1 (0.47) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| SCHEMBL7273091 | 0.84 | MAOB (0.55) | ELANECTSGMAOBALOX5 | |
| SCHEMBL4029644 | 0.83 | MAOB (0.48) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| SCHEMBL7606123 | 0.80 | MAOB (0.50) | ABCB1HTR1ADRD2MAOBALOX5 | |
| SCHEMBL6212452 | 0.78 | PTGER1 (0.60) | ELANECTSGF2HTR1ADRD2 | |
| SCHEMBL1961045 | 0.78 | MAOB (0.49) | ELANECTSGF2MAOB | |
| SCHEMBL1587678 | 0.78 | USP28 (0.50) | ELANECTSGMTNR1AMTNR1BF2 | |
| SCHEMBL8757373 | 0.77 | ELANE (0.71) | ELANECTSGF2HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1357115-A1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | ELANE 4078/4885CTSG 4591/4885MTNR1A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.